Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
2008
2009
2010
Announcements
Articles
Articles and Publications
Campaign
Case Studies
Charge Capture and Pricing
Coding Integrity
Company
Consulting
Craneware Insights Articles
Education
Home
Journey
News & Events
Opportunities
Other
post
Press Releases
Products
Services
Testimonial
Trade Shows
Uncategorized
Uncategorized
Upcoming Events
Value Cycle
Webinars
White Papers

Has the AMA announced a new CPT code to report for booster doses of the Janssen (J&J) COVID-19 vaccine?

Yes. On October 27, 2021, the AMA announced the creation of a new CPT code, 0034A, to report for booster doses of the Janssen COVID-19 vaccine. For your convenience, we have included the full long description for CPT 0034A below.

0034A: Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5×1010 viral particles/0.5 mL dosage; booster dose

Per the AMA press release linked below, CPT 0034A is retroactively effective back to October 20, 2021 – the day the FDA amended the Emergency Use Authorization for the Janssen vaccine to allow for booster doses for certain patient populations.

It is important to highlight that 0034A reflects the booster administration service only. The Janssen vaccine product is reported with CPT 91303.

AMA press release, “AMA announces CPT update to COVID-19 vaccine booster”:
https://www.ama-assn.org/press-center/press-releases/ama-announces-cpt-update-covid-19-vaccine-booster?utm_source=SFMC&utm_medium=email&utm_term=10292021&utm_content=HS_Email_Comm_CPT_News_10_27_21&utm_campaign=HS_Email_Comm_CPT_News_102921&utm_asset_name=HS_Email_Comm_CPT_News_102921&utm_channel_name=Email

FDA news release, Coronavirus (COVID-19) Update: FDA Takes Additional Actions on the Use of a Booster Dose for COVID-19 Vaccines:
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-takes-additional-actions-use-booster-dose-covid-19-vaccines

Skip to toolbar